跳至主要内容
临床试验/ACTRN12616001581459
ACTRN12616001581459已完成未知

Prospective Imaging Study of Ageing: Genes, Brain and Behaviour

QIMR Berghofer Medical Research Institute0 个研究点目标入组 265 人开始时间: 2016年11月16日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
265

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
40 Years 至 80 Years(—)
性别
All

入选标准

  • Overall Study:
  • aged between the ages of 40 and 80
  • fluent in English
  • clinical diagnosis of Alzheimer’s disease (Group 1)
  • meet a research consensus classification of amnestic MCI (Group 2)
  • No current or past history of neurological conditions and consented to participate in GWAS studies at QIMR Berghofer (with existing GWAS information + consent to participate in other HREC approved studies).
  • Completed an MRI exam
  • Neuropsychological testing and Blood sample collection:
  • Participants who have met the overall study inclusion criteria will be recruited into these components of the study.
  • MRI Imaging
  • overall study inclusion criteria
  • MRI clearance
  • All participants who have been granted MRI clearance outlined in the Metals Safety Questionnaire, and have met the inclusion criteria for the Overall study will be included in this component.
  • PET Imaging:
  • Participants who have completed the MRI exam and have met the inclusion criteria for the overall study may be recruited into this component of the study.
  • Smart Sensing Study:
  • All participants who own a smart phone, have completed all other testing components and have met the inclusion criteria for the overall study may be recruited into this component of the study.

排除标准

  • Overall study:
  • *Inability to provide formal consent
  • *Any significant neurological disease (other than Alzheimer's disease) or history of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities
  • *Longstanding (>10 years) history of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
  • *History of major depression, bipolar disorder or schizophrenia that puts assessment of cognitive impairment into question
  • *Any significant disease or unstable medical condition that could affect neuropsychological testing (i.e., chronic renal failure, chronic hepatic disease, severe pulmonary disease)
  • *History of brain injury with significant sequelae (i.e. haemorrhage, oedema, hypoxia) or invasive neurosurgery.
  • Neuropsychological testing and Blood sample collection:
  • Participants who have not met any of the exclusion criteria outlined in the Overall Study will be recruited into these components of the study.
  • Excluded from MRI imaging
  • *presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, metallic fragments near the eyes or spinal cord, or cochlear implant. (Dental fillings do not present a risk for MRI).
  • Excluded from PET Imaging:
  • *Those who are pregnant or breastfeeding
  • *extensive white matter lesions or other neurological conditions are detected at MRI
  • *Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, metallic fragments near the eyes or spinal cord, or cochlear implant. (Dental fillings do not present a risk for MRI).
  • *History of hypersensitivity reaction to Flutemetamol F18, or any other inactive ingredient in Flutemetamol F18
  • Smart Sensing Study:
  • *Participants who do not own a smartphone will not be invited to complete this component of the study.

研究者

相似试验